Content about Vivus

April 17, 2013
Changes to REMS to allow dispensing of Vivus obesity drug in retail

The Food and Drug Administration has approved a modification to a program added to the labeling of an obesity drug to ensure patient safety.

MOUNTAIN VIEW, Calif. — The Food and Drug Administration has approved a modification to a program added to the labeling of an obesity drug to ensure patient safety.

Vivus announced that the FDA had approved changes to the risk evaluation and mitigatin strategy for Qsymia (phentermine and topiramate) extended-release capsules. The amendment to the REMS allows the drug to be dispensed through certified retail pharmacies in addition to the existing network of mail-order pharmacies.

February 1, 2013
Patients taking obesity drug experience improvement in cardiovascular risk factors, study finds

Patients who take a drug for losing weight may experience improvement in multiple cardiovascular disease risk factors, according to a new study.

MOUNTAIN VIEW, Calif. — Patients who take a drug for losing weight may experience improvement in multiple cardiovascular disease risk factors, according to a new study.

September 19, 2012
Vivus launches obesity drug

Drug maker Vivus has released what it called the first new drug in 13 years for chronic weight management in adults.

MOUNTAIN VIEW, Calif. — Drug maker Vivus has released what it called the first new drug in 13 years for chronic weight management in adults.

The company announced the availability of Qsymia (phentermine and topiramate) extended-release capsules, which it is formally introducing to medical professionals this week at the Obesity Society's annual scientific meeting in San Antonio.

February 23, 2012
FDA committee recommends approval for obesity drug

A panel of experts at the Food and Drug Administration has recommended approval for an obesity drug that so far had not met much success at the agency.

MOUNTAIN VIEW, Calif. — A panel of experts at the Food and Drug Administration has recommended approval for an obesity drug that so far had not met much success at the agency.

Vivus announced Wednesday that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving Qnexa (phentermine and topiramate) for obesity in adults. The FDA is not bound by advisory committee votes when it decides whether or not to approve a drug, but usually follows them.

December 7, 2011
Data from Qnexa study presented at World Diabetes Congress

Obese diabetes patients could experience weight loss when taking Vivus' anti-obesity drug, according to an oral presentation at the International Diabetes Federation's World Diabetes Congress in Dubai.

MOUNTAIN VIEW, Calif. — Obese diabetes patients could experience weight loss when taking Vivus' anti-obesity drug, according to an oral presentation at the International Diabetes Federation's World Diabetes Congress in Dubai.